“Central Nervous System Disorder Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019” by Transparency Market Research jots down the details in and around the various factors that drive or restrain this market currently, along with the factors that are expected to influence its growth rate over the coming years. The report focuses on the diseases that affect the spinal cord or the brain, including bipolar disorders, anxiety issues, depression, Alzheimer’s disease, epilepsy, and Parkinson’s disease.
Download Exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1475
The primary fact accountable for the current growth rate portrayed by the global central nervous system disorder drugs market is the speedy growth rate of the geriatric population across the world. The elderly are the leading demographic found to be susceptible to disorders of the central nervous system and thus the healthcare sector is largely dedicated to resolving these issues particularly for this demographic. A massive grey area lies over the treatment for Alzheimer’s as there is currently no treatment option for the disease. Nearly all of the global central nervous system disorder drugs market dedicated to Alzheimer’s is primarily research and development. With the growing number of patients diagnosed with the disease, healthcare organizations, government bodies and even private investors are coming forward to speed up the development of a solid treatment for it.
The key drug segments found in the global central nervous system disorder drugs market include pain drugs, neurology, and psychiatry. Pain management is largely associated to alleviating the pain and symptoms of CNS disease. The drugs in the neurology include all those listed for the treatment of Alzheimer’s disease, narcolepsy, epilepsy, multiple sclerosis, Parkinson’s disease, and migraines. Psychiatry drugs are largely associated with the remaining mental disorders such as ADD, ADHD, bipolar disorders, anxiety, schizophrenia, and depression.
From a geographical perspective, the global central nervous system disorder drugs market is currently being led by North America, and it seems like this region will remain in the lead for the coming years. An advanced healthcare infrastructure, the presence of several key players from the market, and high interest and investments shown by government and private entities is fueling the growth of the market in this region. Similar reasons are attributed to the development of the central nervous system disorder drugs market in Europe, which is in second position from a global perspective.
On the other hand, Asia Pacific is expected to reflect a highly positive scope of opportunities for key players by showing a massive increase in demand. Additionally, this region is a primary location for the burgeoning medical tourism industry, further allowing Asia Pacific to hold a higher potential of generating high revenues in the market.
The key players currently active in the global central nervous system disorder drugs market include Pfizer, GlaxoSmithKline, Johnson & Johnson, Sanofi, Novartis AG, Abbott Laboratories, Merck & Co., Bristol-Meyers Squibb Co., Eli Lilly, UCB, and Astellas Pharma, Inc.
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453